AstraZeneca vaccine: Did the UK benefit from negotiating their contract early?

The Oxford AstraZeneca vaccine has been a source of tension between the United Kingdom and European Union, especially concerning the number of doses each party was due to receive. The UK was able to start administering the drug much faster than the EU, but why was it able to do so? The Fact or Fake team takes a closer look.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting